Please login to the form below

Not currently logged in
Email:
Password:

Pharmalink appoints Dr Heather Cook and Marek Poszepczynski

Strengthens senior management team

Pharmalink Marek PoszepczynskiPharmalink has bolstered its senior management team with the appointment of Dr Heather Cook and Marek Poszepcynski (pictured).

Dr Cook joins the Swedish specialty pharmaceutical company as director of regulatory affairs from Lundbeck, where she headed up its regulatory development projects department.

Prior to her time with Lundbeck, Dr Cook served at AstraZeneca as its global regulatory affairs director for oncology and a number of other senior roles, including scientific director for neuroscience and infection.

Pharmalink's other senior management appointment is Marek Poszepcynski who takes up the role of director of business development.

He arrives at the company from analysts Handelsbanken, where he covered European and Swedish biotechnology stocks, and before that was vice president of business development at Karolinska Development.

Pharmalink's managing director Johan Häggblad said: "These appointments add significant talent and new experience to Pharmalink's management team as the company continues to drive forward its late stage clinical development programs for Nefecon and Busulipo and actively seeks new product opportunities.

“It is a measure of our reputation that such high caliber executives have joined us and I look forward to working with Heather and Marek through what is an exciting stage of development."

Picture credit: Lenita Gahlin

30th October 2012

From: Sales, Regulatory

Share

Tags


Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Watermeadow Medical US

Watermeadow Medical is an award-winning, international agency with offices in Oxford and Manchester, UK and New York, USA. ....

Latest intelligence

Online Physician Communities
Study highlights value of internet for doctors in Eastern Europe
Electronic direct mail is proving popular as online access increases...
England’s clinical commissioning landscape
Who are the real masters in the new NHS?...
How will the new landscape of Hep C treatments affect patients?
The development of new therapeutic agents is set to transform the treatment of hepatitis C over the coming years....